GS-441524

DRUG2 trials

Sponsors

Copycat Sciences LLC, National Center for Advancing Translational Sciences (NCATS)

Conditions

COVID-19

Phase 1

First-in-Human Study of Orally Administered GS-441524 for COVID-19

CompletedNCT04859244

Copycat Sciences LLCCOVID-19

Start: 2021-01-01End: 2021-08-01Updated: 2021-08-10

GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects

WithdrawnNCT06274853

National Center for Advancing Translational Sciences (NCATS)COVID-19

Start: 2024-06-15End: 2024-12-31Updated: 2025-02-14